Investment
Features
FeesSafety
Academy
More
Pluang+

PTC to report Q4 and full-year 2026 results Nov 4, suspends earnings calls amid Schneider Electric acquisition.

Company Fundamentals
19 Oct 2026
PRNewsWire
View Source
Neutral
PTC to report Q4 and full-year 2026 results Nov 4, suspends earnings calls amid Schneider Electric acquisition.

PTC will release its fiscal fourth quarter and full year 2026 financial results on November 4 after market close. The company has suspended its quarterly earnings calls and will no longer provide earnings guidance due to its pending acquisition by Schneider Electric, announced earlier in October. Investors can access the earnings release and financial data on PTC's Investor Relations website. This marks a significant transition as PTC prepares to integrate with Schneider Electric's operations.

PTC's upcoming fiscal fourth quarter and full year 2026 results provide context for market watchers. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 19, 2026 17:02 WIB: Out of 150 priced Technology-sector US stocks, 107 rose and 22 fell today. Notable movers included AXTI at USD 54.14 (+5.19%), CRSR at USD 13.40 (+4.77%), and CIFR at USD 9.39 (+4.57%).

More News

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...

Others
Neutral
24 minutes ago
EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...

Company Fundamentals
Neutral
24 minutes ago
Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

Market News
Bullish
24 minutes ago
Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics announced that Mark Vale, former UPS president and current CEO of Transportation Insight, will join its board and chair the audit committee after its merger with Churchill Capital Corp XI. Vale's extensive experience in global logist...

Company Fundamentals
Bullish
24 minutes ago
JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Market News
Bullish
24 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App